The purpose of this first in human study is to assess safety, tolerability, PK and preliminary clinical activity and to estimate the MTD(s)/RDE(s) of MIK665 (also referred as S64315) as single agent administered intravenously (i.v.) in adult patients with refractory or relapsed lymphoma or multiple myeloma.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Incidence and severity of AEs and SAEs, incl. changes in laboratory parameters, vital signs and ECGs.
Timeframe: 2 years
Incidence of DLTs during the first cycle of treatment with single agent MIK665 during the dose escalation phase only
Timeframe: 2 years
Tolerability: Dose interruptions
Timeframe: 2 years
Tolerability: Dose reductions
Timeframe: 2 years
Tolerability: Dose intensity
Timeframe: 2 years